表紙：新規抗体療法市場：新規抗体タイプ別、標的適応症別、治療法タイプ別、投与経路別、主要地域別：業界動向と世界の予測、2022年～2035年

市場調査レポート

商品コード

1130889

新規抗体療法市場：新規抗体タイプ別、標的適応症別、治療法タイプ別、投与経路別、主要地域別：業界動向と世界の予測、2022年～2035年

Novel Antibody Therapies Market: Distribution by Type of Novel Antibody, Target Indication, Type of Therapy, Route of Administration, and Key Geographical Regions : Industry Trends and Global Forecasts, 2022-2035

出版日: 2023年09月01日 | 発行: Roots Analysis

| ページ情報: 英文 214 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF (Single User License)

USD 4,799 754,114円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷も可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (One-Location Site License)

USD 6,999 1,099,822円

レポートPDFを同一所在地における特定事業ユニットに属する全ての方にてご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Department License)

USD 10,599 1,665,526円

レポートPDFを部署単位で12名様までご利用いただけるライセンスです。同一部署内であれば、地理的に同じ地点に存在する必要はありません。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷も可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Enterprise License)

USD 17,999 2,828,362円

レポートPDFを同社の国内外拠点における全ての方にてご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷も可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=157.14円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

当レポートでは、世界の新規抗体療法市場について調査し、市場の概要とともに、新規抗体タイプ別、標的適応症別、治療法タイプ別、投与経路別、主要地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

分析調査手法と主要なパラメーター
新規抗体療法：開発パイプライン（免疫サイトカイン）
新規抗体療法：開発パイプライン（免疫毒素）
新規抗体療法：開発パイプライン（放射性同位体免疫複合体）
新規抗体療法：開発パイプライン（その他の抗体）
新規抗体療法：開発者一覧

第5章企業プロファイル

Actinium Pharmaceuticals
Molecular Templates
Philogen
Roche
Seagen
Sesen bio
Telix Pharmaceuticals
Y-mAbs Therapeutics

第6章臨床試験分析

分析調査手法と主要なパラメーター
新規抗体治療に焦点を当てた臨床試験のリスト

第7章出版物の分析

第8章特許分析

第9章パートナーシップとコラボレーション

新規抗体療法に焦点を当てたパートナーシップとコラボレーションのリスト

第10章製薬大手

分析調査手法と主要なパラメータ
主要パラメータの採点基準
新規抗体療法に焦点を当てた大手製薬会社のリスト

第11章市場規模と機会分析

予測調査手法と主要な仮定
世界の新規抗体療法市場、2022年～2035年
製品別売上予測（上市済み薬剤）
世界の新規抗体療法市場、2024年および2035年：新規抗体タイプ別
世界の新規抗体療法市場、2026年および2035年：標的適応症別
世界の新規抗体療法市場、2024年および2035年：治療法タイプ別
世界の新規抗体療法市場、2023年および2035年：投与経路別
世界の新規抗体療法市場、2024年および2035年：地域別
製品別売上予測（第Ⅲ相の薬剤）

第12章付録1：表形式のデータ

第13章付録2：企業および組織のリスト

図表

LIST OF TABLES

Table 4.1 Novel Antibody Therapies (Immunocytokines): Development Pipeline
Table 4.2 Novel Antibody Therapies (Immunotoxins): Development Pipeline
Table 4.3 Novel Antibody Therapies (Radioisotope immunoconjugates): Development Pipeline
Table 4.4 Novel Antibody Therapies (Other Antibodies): Development Pipeline
Table 4.5 Novel Antibody Therapies: List of Developers
Table 5.1 Actinium Pharmaceuticals: Product Portfolio
Table 5.2 Recent Developments and Future Outlook
Table 5.3 Molecular Templates: Product Portfolio
Table 5.4 Recent Developments and Future Outlook
Table 5.5 Philogen: Product Portfolio
Table 5.6 Recent Developments and Future Outlook
Table 5.7 Roche: Product Portfolio
Table 5.8 Recent Developments and Future Outlook
Table 5.9 Seagen: Product Portfolio
Table 5.10 Recent Developments and Future Outlook
Table 5.11 Sesen bio: Product Portfolio
Table 5.12 Recent Developments and Future Outlook
Table 5.13 Telix Pharmaceuticals: Product Portfolio
Table 5.14 Recent Developments and Future Outlook
Table 5.15 Y-mAbs Therapeutics: Product Portfolio
Table 5.16 Recent Developments and Future Outlook
Table 6.1 List of Clinical Trials focused on Novel Antibody Therapies (Pre 2016-2022)
Table 7.1 List of Publications focused on Novel Antibody Therapies (2017-2022)
Table 8.1 List of Patents focused on Novel Antibody Therapies (2017-2022)
Table 9.1 Novel Antibody Therapies: List of Partnerships and Collaborations (2014-2021)
Table 10.1 List of Big Pharma Player Focused on Novel Antibody Therapies
Table 11.1 Adcetris: Target Patient Population
Table 11.2 Adcetris: Net Present Value (USD Billion)
Table 11.3 Elzonris: Target Patient Population
Table 11.4 Elzonris: Net Present Value (USD Billion)
Table 11.5 Fibromun: Target Patient Population
Table 11.6 Fibromun: Net Present Value (USD Billion)
Table 11.7 Iomab-B: Target Patient Population
Table 11.8 Iomab-B: Net Present Value (USD Billion)
Table 11.9 Nidlegy: Target Patient Population
Table 11.10 Nidlegy: Net Present Value (USD Billion)
Table 11.11 Pluvicto: Target Patient Population
Table 11.12 Pluvicto: Net Present Value (USD Billion)
Table 11.13 T-Guard: Target Patient Population
Table 11.14 T-Guard: Net Present Value (USD Billion)
Table 11.15 TLX 591: Target Patient Population
Table 11.16 TLX 591: Net Present Value (USD Billion)
Table 11.17 Vicinium: Target Patient Population
Table 11.18 Vicinium: Net Present Value (USD Billion)
Table 12.1 Immunocytokines: Distribution by Status of Development
Table 12.2 Immunocytokines: Distribution by Mechanism of Action
Table 12.3 Immunocytokines: Distribution by Type of Cytokine
Table 12.4 Immunocytokines: Distribution by Status of Development and Type of Cytokine
Table 12.5 Immunocytokines: Distribution by Type of Antigen / Format
Table 12.6 Immunocytokines: Distribution by Dosing Frequency
Table 12.7 Immunocytokines: Distribution by Type of Therapy
Table 12.8 Immunocytokines: Distribution by Mode of Administration
Table 12.9 Immunocytokines: Distribution by Route of Administration
Table 12.10 Immunocytokines: Distribution by Target Disease Indication(s)
Table 12.11 Immunotoxins: Distribution by Status of Development
Table 12.12 Immunotoxins: Distribution by Mechanism of Action
Table 12.13 Immunotoxins: Distribution by Type of Toxin
Table 12.14 Immunotoxins: Distribution by Dosing Frequency
Table 12.15 Immunotoxins: Distribution by Type of Therapy
Table 12.16 Immunotoxins: Distribution by Mode of Administration
Table 12.17 Immunotoxins: Distribution by Immunotoxin Target
Table 12.18 Immunotoxins: Distribution by Special Drug Designation
Table 12.19 Immunotoxins: Distribution by Route of Administration
Table 12.20 Immunotoxins: Distribution by Target Disease Indication(s)
Table 12.21 Radioisotope Immunoconjugates: Distribution by Status of Development
Table 12.22 Radioisotope Immunoconjugates: Distribution by Type of Radioisotopes
Table 12.23 Radioisotope Immunoconjugates: Distribution by Status of Development and Type of Radioisotopes
Table 12.24 Radioisotope Immunoconjugates: Distribution by Route of Administration
Table 12.25 Radioisotope Immunoconjugates: Distribution by Type of Therapy
Table 12.26 Radioisotope Immunoconjugates: Distribution by Dosing Frequency
Table 12.27 Radioisotope Immunoconjugates: Distribution by Mode of Administration
Table 12.28 Radioisotope Immunoconjugates: Distribution by Special Drug Designation
Table 12.29 Radioisotope Immunoconjugates: Distribution by Target Disease Indication(s)
Table 12.30 Novel Antibody Therapies Developers: Distribution by Type of Players
Table 12.31 Novel Antibody Therapies Developers: Distribution by Company Size
Table 12.32 Novel Antibody Therapies Developers: Distribution by Year of Establishment
Table 12.33 Novel Antibody Therapies Developers: Distribution by Location of Headquarters (Region-wise)
Table 12.34 Novel Antibody Therapies Developers: Distribution by Location of Headquarters (Country-wise)
Table 12.35 Novel Antibody Therapies Developers: Distribution by Company Size and Region of Headquarters
Table 12.36 Leading Players: Distribution by Number of Therapeutics
Table 12.37 Molecular Templates: Financial Information
Table 12.38 Philogen: Financial Information
Table 12.39 Roche: Financial Information
Table 12.40 Seagen: Financial Information
Table 12.41 Sesen bio: Financial Information
Table 12.42 Telix Pharmaceuticals: Financial Information
Table 12.43 Y-mAbs Therapeutics: Financial Information
Table 12.44 Clinical Trial Analysis: Distribution by Trial Status
Table 12.45 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, (Pre-2016-April 2022)
Table 12.46 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, (Pre-2016- April 2022)
Table 12.47 Clinical Trial Analysis: Distribution by Trial Phase
Table 12.48 Clinical Trial Analysis: Distribution by Trial Phase and Patients Enrolled
Table 12.49 Clinical Trial Analysis: Distribution by Trial Registration Year and Patients Enrolled
Table 12.50 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 12.51 Clinical Trial Analysis: Distribution by Disease Indication(s)
Table 12.52 Clinical Trial Analysis: Distribution by Study Design
Table 12.53 Most Active Industry Players: Distribution by Number of Trials
Table 12.54 Most Active Non-Industry Players: Distribution by Number of Trials
Table 12.55 Clinical Trial Analysis: Distribution by Type of Treatment
Table 12.56 Clinical Trial Analysis: Distribution by Type of Drug
Table 12.57 Clinical Trial Analysis: Distribution by Top Indication(s) and Trial Phase
Table 12.58 Clinical Trial Analysis: Distribution by Top Indication(s) and Leading Industry Players
Table 12.59 Clinical Trial Analysis: Distribution by Trial Location
Table 12.60 Clinical Trial Analysis: Distribution by Geography and Trial Status
Table 12.61 Publication Analysis: Distribution by Year of Publication
Table 12.62 Publication Analysis: Distribution by Type of Article
Table 12.63 Top Authors: Distribution by Number of Publications
Table 12.64 Key Journals: Distribution by Number of Publications
Table 12.65 Key Journals: Distribution by Impact Factor
Table 12.66 Most Popular Publishers: Distribution by Number of Publications
Table 12.67 Most Popular Copyright Holders: Distribution by Number of Publications
Table 12.68 Patent Analysis: Distribution by Patent Publication Year
Table 12.69 Patent Analysis: Year-wise Distribution of Granted Patents
Table 12.70 Patent Analysis: Distribution by Type of Patent
Table 12.71 Patent Analysis: Distribution by Granted Patents and Patent Applications
Table 12.72 Patent Analysis: Distribution by Geography
Table 12.73 Patent Analysis: Distribution by CPC Symbols
Table 12.74 Patent Analysis: Distribution by Type of Applicant
Table 12.75 Patent Analysis: Distribution by Patent Age
Table 12.76 Leading Industry Players: Distribution by Number of Patents
Table 12.77 Leading Non-Industry Players: Distribution by Number of Patents
Table 12.78 Leading Individual Assignees: Distribution by Number of Patents
Table 12.79 Leading Players: Benchmarking by Patent Characteristics (CPC Symbols)
Table 12.80 Patent Valuation: Distribution by Relative Valuation
Table 12.81 Partnerships and Collaborations: Distribution by Year of Partnership
Table 12.82 Partnerships and Collaborations: Distribution by Type of Partnership
Table 12.83 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 12.84 Most Popular Drug: Distribution by Number of Partnerships
Table 12.85 Partnerships and Collaborations: Distribution by Types of Novel Antibodies
Table 12.86 Partnerships and Collaborations: Distribution by Target Disease Indication(s)
Table 12.87 Partnerships and Collaborations: Distribution by Type of Partnership and Target Indication(s)
Table 12.88 Most Active Players: Distribution by Number of Partnership
Table 12.89 Partnerships and Collaborations: Distribution by Most Active Partner and Type of Partnership
Table 12.90 Regional Distribution of Partnerships
Table 12.91 Intercontinental and Intracontinental Agreements
Table 12.92 Global Novel Antibody Therapies Market, 2022 and 2035 (USD Billion)
Table 12.93 Adcetris Sales Forecast, 2022-2035 (USD Billion) (Base, Conservative, Optimistic)
Table 12.94 Elzonris Sales Forecast, 2022-2035 (USD Billion) (Base, Conservative, Optimistic)
Table 12.95 Pluvicto Sales Forecast, 2022-2035 (USD Billion) (Base, Conservative, Optimistic)
Table 12.96 Global Novel Antibody Therapies Market, 2022 and 2035: Distribution by Type of Novel Antibodies
Table 12.97 Novel Antibody Therapies Market for Immunocytokines, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.98 Novel Antibody Therapies Market for Immunotoxin, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.99 Novel Antibody Therapies Market for Radioisotopes Immunoconjugates, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.100 Global Novel Antibody Therapies Market, 2022 and 2035: Distribution by Target Disease Indication(s)
Table 12.101 Novel Antibody Therapies Market for Acute Myeloid Leukemia, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.102 Novel Antibody Therapies Market for Bladder Cancer, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.103 Novel Antibody Therapies Market for Diffuse Large B-cell Lymphoma, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.104 Novel Antibody Therapies Market for Graft-versus-host disease, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.105 Novel Antibody Therapies Market for Melanoma, 2022-2035 (USD Billion) (Base, Conservative, Optimistic)
Table 12.106 Novel Antibody Therapies Market for Prostate Cancer, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.107 Novel Antibody Therapies Market for Soft-tissue sarcoma, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.108 Global Novel Antibody Therapies Market, 2022 and 2035: Distribution by Type of Therapy
Table 12.109 Novel Antibody Therapies Market for Combination Therapy, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.110 Novel Antibody Therapies Market for Monotherapy, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion))
Table 12.111 Global Novel Antibody Therapies Market, 2022 and 2035: Distribution by Route of Administration
Table 12.112 Novel Antibody Therapies Market for Intratumoral Drugs, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.113 Novel Antibody Therapies Market for Intravenous Drugs, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.114 Novel Antibody Therapies Market for Intravesical Drugs, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.115 Global Novel Antibody Therapies Market, 2022 and 2035: Distribution by Geography
Table 12.116 Novel Antibody Therapies Market in North America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.117 Novel Antibody Therapies Market in Europe, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.118 Novel Antibody Therapies Market in Asia Pacific Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.119 Adcetris Sales Forecast, 2022-2035 (USD Billion) (Base, Conservative, Optimistic)
Table 12.120 Fibromun Sales Forecast, 2022-2035 (USD Billion) (Base, Conservative, Optimistic)
Table 12.121 Iomab-B Sales Forecast, 2022-2035 (USD Billion) (Base, Conservative, Optimistic)
Table 12.122 Nidlegy Sales Forecast, 2022-2035 (USD Billion) (Base, Conservative, Optimistic)
Table 12.123 T-Guard Sales Forecast, 2022-2035 (USD Billion) (Base, Conservative, Optimistic)
Table 12.124 TLX 591 Sales Forecast, 2022-2035 (USD Billion) (Base, Conservative, Optimistic)
Table 12.125 Vicinium sales Forecast, 2022-2035 (USD Billion) (Base, Conservative, Optimistic)

LIST OF FIGURES

Figure 3.1 Types of Novel Antibody Therapies
Figure 3.2 Mechanism of Action of ADEPT
Figure 3.3 Mechanism of Action of TCR like Antibodies
Figure 3.4 Mechanism of Action of Radioisotope Immunoconjugates
Figure 3.5 Mechanism of Action of Immunotoxins
Figure 3.6 Mechanism of Action of Intracellular Antibody
Figure 3.7 Mechanism of Action of Immunocytokines
Figure 3.8 Therapeutic Antibodies: Development Approaches
Figure 4.1 Immunocytokines: Distribution by Status of Development
Figure 4.2 Immunocytokines: Distribution by Mechanism of Action
Figure 4.3 Immunocytokines: Distribution by Type of Cytokine
Figure 4.4 Immunocytokines: Distribution by Status of Development and Type of Cytokine
Figure 4.5 Immunocytokines: Distribution by Type of Antigen / Format
Figure 4.6 Immunocytokines: Distribution by Dosing Frequency
Figure 4.7 Immunocytokines: Distribution by Type of Therapy
Figure 4.8 Immunocytokines: Distribution by Mode of Administration
Figure 4.9 Immunocytokines: Distribution by Route of Administration
Figure 4.10 Immunocytokines: Distribution by Target Disease Indication(s)
Figure 4.11 Immunotoxins: Distribution by Status of Development
Figure 4.12 Immunotoxins: Distribution by Mechanism of Action
Figure 4.13 Immunotoxins: Distribution by Type of Toxin
Figure 4.14 Immunotoxins: Distribution by Dosing Frequency
Figure 4.15 Immunotoxins: Distribution by Type of Therapy
Figure 4.16 Immunotoxins: Distribution by Mode of Administration
Figure 4.17 Immunotoxins: Distribution by Immunotoxin Target
Figure 4.18 Immunotoxins: Distribution by Special Drug Designation
Figure 4.19 Immunotoxins: Distribution by Route of Administration
Figure 4.20 Immunotoxins: Distribution by Target Disease Indication(s)
Figure 4.21 Radioisotope Immunoconjugates: Distribution by Status of Development
Figure 4.22 Radioisotope Immunoconjugates: Distribution by Type of Radioisotopes
Figure 4.23 Radioisotope Immunoconjugates: Distribution by Status of Development and Type of Radioisotopes
Figure 4.24 Radioisotope Immunoconjugates: Distribution by Route of Administration
Figure 4.25 Radioisotope Immunoconjugates: Distribution by Type of Therapy
Figure 4.26 Radioisotope Immunoconjugates: Distribution by Dosing Frequency
Figure 4.27 Radioisotope Immunoconjugates: Distribution by Mode of Administration
Figure 4.28 Radioisotope Immunoconjugates: Distribution by Special Drug Designation
Figure 4.29 Radioisotope Immunoconjugates: Distribution by Target Disease Indication(s)
Figure 4.30 Novel Antibody Therapies Developers: Distribution by Type of Player
Figure 4.31 Novel Antibody Therapies Developers: Distribution by Company Size
Figure 4.32 Novel Antibody Therapies Developers: Distribution by Year of Establishment
Figure 4.33 Novel Antibody Therapies Developers: Distribution by Location of Headquarters (Region-wise)
Figure 4.34 Novel Antibody Therapies Developers: Distribution by Location of Headquarters (Country-wise)
Figure 4.35 Novel Antibody Therapies Developers: Distribution by Company Size and Region of Headquarters
Figure 4.36 Leading Players: Distribution by Number of Therapeutics
Figure 5.1 Molecular Templates: Financial Information (2016-2021)
Figure 5.2 Philogen: Financial Information (2017-2021)
Figure 5.3 Roche: Financial Information (2016-2021)
Figure 5.4 Seagen: Financial Information (2016-2021)
Figure 5.5 Sesen bio: Financial Information (2020-2021)
Figure 5.6 Telix Pharmaceuticals: Financial Information (2018-2021)
Figure 5.7 Y-mAbs Therapeutics: Financial Information (2020-2021)
Figure 6.1 Clinical Trial Analysis: Distribution by Trial Status
Figure 6.2 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, (Pre-2016-April 2022)
Figure 6.3 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, (Pre-2001- April 2022)
Figure 6.4 Clinical Trial Analysis: Distribution by Trial Phase
Figure 6.5 Clinical Trial Analysis: Distribution by Trial Phase and Patients Enrolled
Figure 6.6 Clinical Trial Analysis: Distribution by Trial Registration Year and Patients Enrolled
Figure 6.7 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 6.8 Clinical Trial Analysis: Distribution by Disease Indication(s)
Figure 6.9 Clinical Trial Analysis: Distribution by Study Design
Figure 6.10 Most Active Industry Players: Distribution by Number of Trials
Figure 6.11 Most Active Non-Industry Players: Distribution by Number of Trials
Figure 6.12 Clinical Trial Analysis: Distribution by Type of Treatment
Figure 6.13 Clinical Trial Analysis: Distribution by Type of Drug
Figure 6.14 Word Cloud Analysis: Emerging Focus Areas
Figure 6.15 Clinical Trial Analysis: Distribution by Top Indication(s) and Trial Phase
Figure 6.16 Clinical Trial Analysis: Distribution by Top Indication(s) and Leading Industry Players
Figure 6.17 Clinical Trial Analysis: Distribution by Trial Location
Figure 6.18 Clinical Trial Analysis: Distribution by Geography and Trial Status
Figure 7.1 Publication Analysis: Distribution by Year of Publication
Figure 7.2 Word Cloud Analysis: Emerging Focus Areas
Figure 7.3 Publication Analysis: Distribution by Type of Article
Figure 7.3 Top Authors: Distribution by Number of Publications
Figure 7.4 Key Journals: Distribution by Number of Publications
Figure 7.5 Key Journals: Distribution by Impact Factor
Figure 7.6 Most Popular Publishers: Distribution by Number of Publications
Figure 7.7 Most Popular Copyright Holders: Distribution by Number of Publications
Figure 8.1 Patent Analysis: Distribution by Patent Publication Year
Figure 8.2 Patent Analysis: Year-wise Distribution of Granted Patents
Figure 8.3 Patent Analysis: Distribution by Type of Patent
Figure 8.4 Patent Analysis: Distribution by Granted Patents and Patent Applications
Figure 8.5 Patent Analysis: Distribution by Geography
Figure 8.6 Patent Analysis: Distribution by CPC Symbols
Figure 8.7 Patent Analysis: Distribution by Type of Applicant
Figure 8.8 Patent Analysis: Distribution of Patents by Age
Figure 8.9 Word Cloud Analysis: Emerging Focus Areas
Figure 8.10 Leading Industry Players: Distribution by Number of Patents
Figure 8.11 Leading Non-Industry Players: Distribution by Number of Patents
Figure 8.12 Leading Individual Assignees: Distribution by Number of Patents
Figure 8.13 Leading Players: Benchmarking by Patent Characteristics (CPC Symbols)
Figure 8.14 Patent Valuation: Distribution by Relative Valuation
Figure 9.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 9.4 Most Popular Drug: Distribution by Number of Partnerships
Figure 9.5 Partnerships and Collaborations: Distribution by Types of Novel Antibodies
Figure 9.6 Partnerships and Collaborations: Distribution by Target Disease Indication(s)
Figure 9.7 Partnerships and Collaborations: Distribution by Type of Partnership and Target Indication(s)
Figure 9.8 Most Active Players: Distribution by Number of Partnership
Figure 9.9 Partnerships and Collaborations: Distribution by Most Active Player and Type of Partnership
Figure 9.10 Regional Distribution of Partnerships
Figure 9.11 Intercontinental and Intracontinental Agreements
Figure 10.1 Distribution by Supplier Strength
Figure 10.2 Distribution by Portfolio Strength
Figure 10.3 Distribution by Portfolio Diversity
Figure 10.4 Benchmarking: Spider Web Analysis
Figure 10.5 Benchmarking: Harvey Ball Analysis
Figure 10.6 Benchmarking: Wind Rose Chart
Figure 11.1 Global Novel Antibody Therapies Market, 2022-2035 (USD Billion)
Figure 11.2 Adcetris Sales Forecast, 2022-2035 (USD Billion)
Figure 11.3 Elzonris Sales Forecast, 2022-2035 (USD Billion)
Figure 11.4 Pluvicto Sales Forecast, 2022-2035 (USD Billion)
Figure 11.5 Global Novel Antibody Therapies Market, 2022 and 2035: Distribution by Type of Novel Antibodies
Figure 11.6 Novel Antibody Therapies Market for Immunocytokines, 2022-2035 (USD Billion)
Figure 11.7 Novel Antibody Therapies Market for Immunotoxin, 2022-2035 (USD Billion)
Figure 11.8 Novel Antibody Therapies Market for Radioisotopes Immunoconjugates, 2022-2035 (USD Billion)
Figure 11.9 Global Novel Antibody Therapies Market, 2022 and 2035: Distribution by Target Disease Indication(s)
Figure 11.10 Novel Antibody Therapies Market for Acute Myeloid Leukemia, 2022-2035 (USD Billion)
Figure 11.11 Novel Antibody Therapies Market for Bladder Cancer, 2022-2035 (USD Billion)
Figure 11.12 Novel Antibody Therapies Market for Diffuse Large B-cell Lymphoma, 2022-2035 (USD Billion)
Figure 11.13 Novel Antibody Therapies Market for Graft-versus-host disease, 2022-2035 (USD Billion)
Figure 11.14 Novel Antibody Therapies Market for Melanoma, 2022-2035 (USD Billion)
Figure 11.15 Novel Antibody Therapies Market for Prostate Cancer, 2022-2035 (USD Billion)
Figure 11.16 Novel Antibody Therapies Market for Soft-tissue sarcoma, 2022-2035 (USD Billion)
Figure 11.17 Global Novel Antibody Therapies Market, 2022 and 2035: Distribution by Type of Therapy
Figure 11.18 Novel Antibody Therapies Market for Combination Therapy, 2022-2035 (USD Billion)
Figure 11.19 Novel Antibody Therapies Market for Monotherapy, 2022-2035 (USD Billion)
Figure 11.20 Global Novel Antibody Therapies Market, 2022 and 2035: Distribution by Route of Administration
Figure 11.21 Novel Antibody Therapies Market for Intratumoral Drugs, 2022-2035 (USD Billion)
Figure 11.22 Novel Antibody Therapies Market for Intravenous Drugs, 2022-2035 (USD Billion)
Figure 11.23 Novel Antibody Therapies Market for Intravesical Drugs, 2022-2035 (USD Billion)
Figure 11.24 Global Novel Antibody Therapies Market, 2022 and 2035: Distribution by Geography
Figure 11.25 Novel Antibody Therapies Market in North America, 2022-2035 (USD Billion)
Figure 11.26 Novel Antibody Therapies Market in Europe, 2022-2035 (USD Billion)
Figure 11.27 Novel Antibody Therapies Market in Asia Pacific, 2022-2035 (USD Billion)
Figure 11.28 Adcetris: Target Patient Population
Figure 11.29 Adcetris Sales Forecast, 2022-2035 (USD Billion)
Figure 11.30 Fibromun: Target Patient Population
Figure 11.31 Fibromun Sales Forecast, 2022-2035 (USD Billion)
Figure 11.32 Iomab-B: Target Patient Population
Figure 11.33 Iomab-B Sales Forecast, 2022-2035 (USD Billion)
Figure 11.34 Nidlegy: Target Patient Population
Figure 11.35 Nidlegy Sales Forecast, 2022-2035 (USD Billion)
Figure 11.36 T-Guard: Target Patient Population
Figure 11.37 T-Guard Sales Forecast, 2022-2035 (USD Billion)
Figure 11.38 TLX 591: Target Patient Population
Figure 11.39 TLX 591 Sales Forecast, 2022-2035 (USD Billion)
Figure 11.40 Vicinium: Target Patient Population
Figure 11.41 Vicinium Forecast, 2022-2035 (USD Billion)

Product Code: RA100378

INTRODUCTION

Cancer is known to be one of the leading causes of deaths, worldwide. In fact, as per the annual statistics reported by the American Cancer Society (ACS) indicate that, in 2022, around 1.9 million individuals are likely to be diagnosed with various types of cancer in the US. Further, it is estimated that, by the end of 2040, 27.5 million new cancer cases will be added to the global numbers, exerting tremendous physical, emotional and financial strain on affected individuals, their families, communities and national health systems. Although several conventional treatment options, including chemotherapy, radiation therapy and surgery are available to control disease progression and keep malignant cells from spreading throughout the body, these therapies have demonstrated limited efficacy in late-stage cancers. Moreover, traditional chemotherapy and radiation therapy have negative effects on patients' quality of life due to their non-specific and extremely toxic nature. Amidst the recent initiatives undertaken to develop more targeted anti-cancer therapies, novel antibody therapies have emerged to be one of the most suitable option, having demonstrated the capability to selectively target and eliminate tumor cells. The novel antibody therapies include different classes of antibodies, which are capable of killing or inhibiting disease-causing agents. Multiple antibody formats have been engineered to enhance therapeutic efficacy and target proteins that are expressed on the surface of the affected cells. This has opened a new target space for the development of antibody therapeutics and techniques, facilitating tools to uniquely distinguish malignantly transformed cells from regular cells. Various novel antibody therapies such as immuocytokines, immunotoxins, radioimmunoconjugates and intrabodies are being investigated as a therapeutic modality across multiple clinical trials, particularly as anti-cancer agents.

Till date, six novel antibody therapies, including Adcetris® (mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, T-cell lymphoma and Hodgkin's disease), Elzonris® (Blastic plasmacytoid dendritic cell neoplasm) Lumoxiti® (Hairy cell leukemia), Pluvicto™ (Prostate cancer), Vicineum™ (Bladder cancer) and Zevalin (Lymphoma) have so far been evaluated and approved for various oncological disorders. In addition, more than 130 novel antibody therapies are being evaluated in various preclinical and clinical stages. Currently, more than 50 companies and academic / research institutes are engaged in the development of novel antibody therapies with enhanced efficacy and several promising leads are anticipated to be commercially launched over the coming decade. Over 4,500 patents related to novel antibodies have been recently filed / granted, demonstrating the innovation and continuous research efforts in this domain. In addition, multiple collaborations have been inked between industry / academic stakeholders to advance the development of various pipeline molecules. Moreover, with the active involvement of big pharma players as well as new entrants, the development pipeline of the novel antibody therapies is likely to expand further. Driven by the growing interest of various stakeholders and encouraging clinical research results, the novel antibody therapies market is anticipated to witness steady growth over the coming years.

SCOPE OF THE REPORT

The 'Novel Antibody Therapies Market, 2022-2035: Distribution by Type of Novel Antibody (Immunocytokines, Immunotoxins and Radioisotope Immunoconjugates), Target Indication (Acute Myeloid Leukemia, Bladder Cancer, Diffuse Large B-cell Lymphoma, Graft-versus-host disease, Melanoma Prostate Cancer and Soft-tissue Sarcoma), Type of Therapy (Combination Therapy and Monotherapy), Route of Administration (Intratumoral, Intravenous and Intravesical), and Key Geographical Regions (North America, Europe and Asia-Pacific): Industry Trends and Global Forecasts, 2022-2035' report features an extensive study on the current market landscape, offering an informed opinion on the likely evolution of the novel antibody therapies in the treatment of various diseases. The study presents an in-depth analysis, highlighting the diverse capabilities of players engaged in this domain, across different geographies. In addition to other elements, the report includes:

A general overview of novel antibody therapies including information on the different types of novel antibody therapies. In addition, the chapter presents details on the novel antibody therapies (antibody-directed enzyme prodrug therapy, TCR like antibodies, radioisotope immunoconjugates, immunotoxins, intracellular antibody and immunocytokines). It also features information on developmental approaches of novel antibody therapies, limitations, and future of novel antibody therapies.

A detailed review of the current market landscape of immunocytokines, based on several relevant parameters such as status of development (phase III, phase II, phase I and preclinical stage), mechanism of action (inhibition, modulation and stimulation), type of cytokine, type of antigen / format, dosing frequency, type of therapy (monotherapy and combination therapy), mode of administration (injection and infusion), route of administration (intravenous, intratumoral and subcutaneous), type of therapy and target disease indication(s).

A detailed review of the current market landscape of immunotoxins based on several relevant parameters such as status of development (marketed, BLA registration, phase III, phase II phase I and preclinical stage), mechanism of action (inhibition, modulation and stimulation), type of toxin, dosing frequency, type of therapy (monotherapy and combination therapy), mode of administration (injection and infusion), immunotoxin target, route of administration (intravenous, intravesical, intraperitoneal, intratumoral and intrathecal), and target disease indication(s).

A detailed review of the current market landscape of radioisotope immunoconjugates based on several relevant parameters such as status of development (marketed, phase III, phase II phase I and preclinical stage), type of radioisotope, route of administration (Intravenous, intracerebroventricular and intraperitoneal), type of therapy (monotherapy and combination therapy), dosing frequency, mode of administration (injection and infusion) and target disease indication(s). In addition, the chapter includes a list of novel antibody therapies with special designations. Further, the chapter presents a list of players developing novel antibody therapies along with information on their year of establishment, company size and location of headquarters.

Elaborate profiles of the key players engaged in the development of novel antibody therapies (shortlisted on the basis of number of drugs). Each profile features a brief overview of the company, its financial information (if available), details on its product portfolio and a section on recent developments and an informed future outlook.

An in-depth analysis of completed, ongoing and planned clinical studies of various novel antibody therapies, highlighting prevalent trends across different parameters, such as current trial status, trial registration year, trial phase, enrolled patient population, type of sponsor / collaborator, study design, leading industry and non-industry players (in terms of number of trials conducted), key indication(s), type of treatment, type of drug, emerging focus areas and regional distribution of trials.

A detailed review of more than 570 peer-reviewed, scientific articles related to research on novel antibody therapies, which have been published since 2017, based on parameters, such as year of publication, type of article, emerging focus areas, top authors, key journals, most popular publisher and copyright holders.

An insightful analysis of the patents filed / granted for novel antibody therapies, between 2017- 2021, based on various relevant parameters, such as patent publication year, type of patent, geographical location, CPC symbols, type of applicant, patent age, emerging focus areas, leading individual assignees, industry and non-industry players (in terms of number of patents granted / filed) and patent characteristics. In addition, the chapter includes a detailed patent benchmarking and an insightful valuation analysis.

An analysis of the partnerships that have been established in this domain since 2018, covering instances of acquisition, clinical trial agreement, commercialization agreement, distribution agreement, manufacturing agreement, product development agreement, product development and commercialization agreement, research and development agreement, supply agreement and other relevant type of deals.

An analysis of big pharma players engaged in the field of novel antibody therapies, featuring various insightful representations, such as spider web analysis, Harvey ball analysis and wind rose chart, based on several relevant parameters, such as number of therapeutics under development, type of novel antibody, status of development, number of target indications, number of partnerships, number of patents and years of experience.

One of the key objectives of the report was to identify the primary growth drivers and estimate the future growth opportunity associated with novel antibody therapies market in the mid to long term. Based on parameters, such as historical sales, target patient population, likely adoption rates and expected pricing, we have provided informed estimates on the likely evolution of the market for the period 2022-2035. Our year wise projections of the current and forecasted opportunity within the novel antibody therapies market have further been segmented across type of novel antibody (immunocytokines, immunotoxins, and radioisotope immunoconjugates), target indication (acute myeloid leukemia, bladder cancer, diffuse large b-cell lymphoma, graft-versus-host disease, melanoma prostate cancer, and soft-tissue sarcoma), type of therapy (Combination Therapy and Monotherapy), route of administration (intratumoral, intravenous and intravesical), key geographical regions (North America, Europe and Asia-Pacific). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.

RESEARCH METHODOLOGY

The data presented in this report has been gathered via secondary research. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and segments. Wherever possible, the available data has been validated from multiple sources of information.

The secondary sources of information include:

Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Industry analysts' views

While the focus has been on forecasting the market till 2035, the report also provides our independent view on various non-commercial trends emerging in the industry. The opinions are solely based on our knowledge, research and understanding of the relevant market trends gathered from various secondary sources of information.

KEY QUESTIONS ANSWERED

Who are the leading industry and non-industry players engaged in the development of novel antibody therapies?

Which novel antibody therapies are being developed across early and late stages of development?

Which geographies are the most active in conducting clinical trials related to novel antibody therapies?

What is the focus area of various publications related to the novel antibody therapies?

Which are the leading funding institutes / centers supporting the research related to novel antibody therapies?

What kind of partnership models are commonly adopted by industry stakeholders?

What are the different initiatives undertaken by big pharma players for the development of novel antibody therapies in the recent past?

How is the current and future market opportunity, related to novel antibody therapies likely to be distributed across key market segments?

CHAPTER OUTLINES

Chapter 2 provides an executive summary of the key insights captured during our research. It offers a high-level view on the likely evolution of the novel antibody therapies market in the mid to long term.

Chapter 3 provides a general overview of novel antibody therapies including information on the different types of novel antibody therapies. In addition, the chapter presents details on the novel antibody therapies (Antibody-Directed Enzyme Prodrug Therapy, TCR like Antibodies, Radioisotope Immunoconjugates, Immunotoxins, Intracellular Antibody and Immunocytokines). It also features information on developmental approaches of novel antibody therapies, limitations, and future of novel antibody therapies.

Chapter 4 provides an overview of the current market landscape of novel antibody therapies, such as immunocytokines, immunotoxins and radioisotopes immunoconjugates. In addition the chapter includes a detailed analysis of these antibody therapies based on several relevant parameters. Immunocytokines have been analyzed based on status of development (phase III, phase II, phase I and preclinical stage), mechanism of action (inhibition, modulation and stimulation), type of cytokine, type of antigen / format, dosing frequency type of therapy(monotherapy and combination therapy), mode of administration (injection and infusion), route of administration (intravenous, Intratumoral and subcutaneous), type of therapy and target disease indication(s). Immunotoxins have been analyzed based on status of development (marketed, BLA registration, phase III, phase II phase I and preclinical stage), mechanism of action (inhibition, modulation and stimulation), type of toxin, dosing frequency, type of therapy (monotherapy and combination therapy), mode of administration (injection and infusion), immunotoxin target, route of administration (intravenous, intravesical, intraperitoneal, Intratumoral and intrathecal) and target disease indication(s). Radioisotopes Immunoconjugates have been analyzed based on status of development (marketed, phase III, phase II phase I and preclinical stage), type of radioisotopes, route of administration (Intravenous, Intracerebroventricular and Intraperitoneal), type of therapy (monotherapy and combination therapy), dosing frequency mode of administration (injection and infusion) and target disease indication(s).

Chapter 5 includes detailed profiles of key players engaged in the development of novel antibody therapies. Each profile features a brief overview of the company, its financial information (if available), details on its product portfolio, recent developments and an informed future outlook.

Chapter 6 provides information on more than 550 completed, ongoing and planned clinical studies of novel antibody therapies, based on different parameters, such as trial status, trial registration year, trial phase, enrolled patient population, type of sponsor / collaborator and study design. In addition, the chapter highlights leading industry and non-industry players, key indication(s), type of drug, emerging focus areas and regional distribution of trials.

Chapter 7 features a detailed review of more than 570 peer-reviewed, scientific articles related to research on novel antibody therapies, based on parameters, such as year of publication, emerging focus area, top authors, key research journals, popular publisher and copyright holders.(in terms of number of articles published).

Chapter 8 features an in-depth analysis of the patents that have been filed / granted for novel antibody therapies, between 2017- 2021, on the basis of various relevant parameters, such as patent publication year, type of patent, geographical location, CPC symbols, type of applicant, patent age, emerging focus areas, leading industry and non-industry players (in terms of number of patents granted / filed) and patent characteristics. In addition, it includes detailed patent benchmarking and an insightful valuation analysis.

Chapter 9 features an analysis of the partnerships that have been established in this domain, covering instances of acquisition, clinical trial agreement, commercialization agreement, distribution agreement, manufacturing agreement, product development agreement, product development and commercialization agreement, research and development agreement, supply agreement and other relevant types of deals.

Chapter 10 includes an analysis of big pharma players engaged in the field of novel antibody therapies, featuring different insightful representations, such as spider web analysis, Harvey ball analysis and wind rose chart, based on several relevant parameters, such as number of therapeutics under development, type of novel antibody, status of development, number of target indication, number of partnerships, number of patents and years of experience.

Chapter 11 presents an insightful market forecast analysis, highlighting the future potential of the novel antibody therapies market till the year 2035. It includes future sales projections of novel antibody therapies that are either marketed or are likely to be marketed within the next few years. In order to provide a detailed future outlook, our projections have been segmented across type of novel antibody (immunocytokines, immunotoxins, and radioisotope immunoconjugates), target indication (acute myeloid leukemia, bladder cancer, diffuse large b-cell lymphoma, graft-versus-host disease, melanoma prostate cancer, and soft-tissue sarcoma), type of therapy (Combination Therapy and Monotherapy), route of administration (intratumoral, intravenous and intravesical), key geographical regions (North America, Europe and Asia-Pacific).

Chapter 12 is an appendix that contains tabulated data and numbers for all the figures in the report.

Chapter 13 is an appendix that provides the list of companies and organizations mentioned in the report.

1. PREFACE

1.1. Scope of the Report
1.2 Market Segmentation
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

3.1. Overview of Novel Antibody Therapies
3.2. Types of Novel Antibody Therapies
- 3.2.1. Antibody-Directed Enzyme Prodrug Therapy (ADEPT)
  - 3.2.1.1. Mechanism of Action of ADEPT
  - 3.2.1.2. Advantages of ADEPT
  - 3.2.1.3. Disadvantages of ADEPT
- 3.2.2. TCR like Antibodies
  - 3.2.2.1. Mechanism of Action of TCR like Antibodies
  - 3.2.2.2. Advantages of TCR like Antibodies
  - 3.2.2.3. Disadvantages of TCR like Antibodies
- 3.2.3. Radioisotope Immunoconjugates
  - 3.2.3.1. Mechanism of Action of Radioisotope Immunoconjugates
  - 3.2.3.2. Advantages of Radioisotope Immunoconjugates
  - 3.2.3.3. Disadvantages of Radioisotope Immunoconjugates
- 3.2.4. Immunotoxins
  - 3.2.4.1. Mechanism of Action of Immunotoxins
  - 3.2.4.2. Advantages of Immunotoxins
  - 3.2.4.3. Disadvantages of Immunotoxins
- 3.2.5. Intracellular Antibody
  - 3.2.5.1. Mechanism of Action of Intracellular Antibody
  - 3.2.5.2. Advantages of Intracellular Antibody
  - 3.2.5.3. Disadvantages of Intracellular Antibody
- 3.2.6. Immunocytokines
  - 3.2.6.1. Mechanism of Action of Immunocytokines
  - 3.2.6.2. Advantages of Immunocytokines
  - 3.2.6.3. Disadvantages of Immunocytokines
3.3. Therapeutic Antibodies: Development Approaches
3.4. Future Perspectives

4. NOVEL ANTIBODY THERAPIES: MARKET LANDSCAPE

4.1. Analysis Methodology and Key Parameters
4.2. Novel Antibody Therapies: Development Pipeline (Immunocytokines)
- 4.2.1. Analysis by Status of Development
- 4.2.2. Analysis by Mechanism of Action
- 4.2.3. Analysis by Type of Cytokine
- 4.2.4. Analysis by Status of Development and Type of Cytokine
- 4.2.5. Analysis by Type of Antigen / Format
- 4.2.6. Analysis by Dosing Frequency
- 4.2.7. Analysis by Type of Therapy
- 4.2.8. Analysis by Mode of Administration
- 4.2.9. Analysis by Route of Administration
- 4.2.10. Analysis by Target Disease Indication(s)
4.3. Novel Antibody Therapies: Development Pipeline (Immunotoxins)
- 4.3.1. Analysis by Status of Development
- 4.3.2. Analysis by Mechanism of Action
- 4.3.3. Analysis by Type of Toxin
- 4.3.4. Analysis by Dosing Frequency
- 4.3.5. Analysis by Type of Therapy
- 4.3.6. Analysis by Mode of Administration
- 4.3.7. Analysis by Immunotoxin Target
- 4.3.8. Analysis by Special Drug Designation
- 4.3.9. Analysis by Route of Administration
- 4.3.10. Analysis by Target Disease Indication(s)
4.4. Novel Antibody Therapies: Development Pipeline (Radioisotope Immunoconjugates)
- 4.4.1. Analysis by Status of Development
- 4.4.2. Analysis by Type of Radioisotopes
- 4.4.3. Analysis by Status of Development and Type of Radioisotopes
- 4.4.4. Analysis by Route of Administration
- 4.4.5. Analysis by Type of Therapy
- 4.4.6. Analysis by Dosing Frequency
- 4.4.7. Analysis by Mode of Administration
- 4.4.8. Analysis by Special Drug Designation
- 4.4.9. Analysis by Target Disease Indication(s)
4.5. Novel Antibody Therapies: Development Pipeline (Other Antibodies)
4.6. Novel Antibody Therapies: List of Developers
- 4.6.1. Analysis by Type of Player
- 4.6.2. Analysis by Company Size
- 4.6.3. Analysis by Year of Establishment
- 4.6.4. Analysis by Location of Headquarters (Region-wise)
- 4.6.5. Analysis by Location of Headquarters (Country-wise)
- 4.6.6. Analysis by Company Size and Region of Headquarters
- 4.6.7. Leading Players: Analysis by Number of Therapeutics

5. COMPANY PROFILES

5.1. Actinium Pharmaceuticals
- 5.1.1. Company Overview
- 5.1.2. Financial Information
- 5.1.3. Product Portfolio
- 5.1.4. Recent Developments and Future Outlook
5.2. Molecular Templates
- 5.2.1. Company Overview
- 5.2.2. Financial Information
- 5.2.3. Product Portfolio
- 5.2.4. Recent Developments and Future Outlook
5.3. Philogen
- 5.3.1. Company Overview
- 5.3.2. Financial Information
- 5.3.3. Product Portfolio
- 5.3.4. Recent Developments and Future Outlook
5.4. Roche
- 5.4.1. Company Overview
- 5.4.2. Financial Information
- 5.4.3. Product Portfolio
- 5.4.4. Recent Developments and Future Outlook
5.5. Seagen
- 5.5.1. Company Overview
- 5.5.2. Financial Information
- 5.5.3. Product Portfolio
- 5.5.4. Recent Developments and Future Outlook
5.6. Sesen bio
- 5.6.1. Company Overview
- 5.6.2. Financial Information
- 5.6.3. Product Portfolio
- 5.6.4. Recent Developments and Future Outlook
5.7. Telix Pharmaceuticals
- 5.7.1. Company Overview
- 5.7.2. Financial Information
- 5.7.3. Product Portfolio
- 5.7.4. Recent Developments and Future Outlook
5.8. Y-mAbs Therapeutics
- 5.8.1. Company Overview
- 5.8.2. Financial Information
- 5.8.3. Product Portfolio
- 5.8.4. Recent Developments and Future Outlook

6. CLINICAL TRIAL ANALYSIS

6.1. Analysis Methodology and Key Parameters
6.2. List of Clinical Trials Focused on Novel Antibody Therapies
- 6.2.1. Analysis by Trial Status
- 6.2.2. Analysis by Trial Registration Year
- 6.2.3. Analysis by Trial Registration Year and Trial Status
- 6.2.4. Analysis by Trial Phase
- 6.2.5. Analysis by Trial Phase and Patients Enrolled
- 6.2.6. Analysis by Trial Registration Year and Patients Enrolled
- 6.2.7. Analysis by Type of Sponsor / Collaborator
- 6.2.8. Analysis by Disease Indication(s)
- 6.2.9. Analysis by Study Design
- 6.2.10. Most Active Industry Players: Analysis by Number of Trials
- 6.2.11. Most Active Non-Industry Players: Analysis by Number of Trials
- 6.2.12. Analysis by Type of Treatment
- 6.2.13. Analysis by Type of Drug
- 6.2.14. Word Cloud Analysis: Emerging Focus Areas
- 6.2.15. Analysis by Top Indication(s) and Trial Phase
- 6.2.16. Analysis by Top Indication(s) and Leading Industry Players
- 6.2.17. Analysis by Trial Location
- 6.2.18. Analysis by Geography and Trial Status

7. PUBLICATION ANALYSIS

7.1. Analysis Methodology and Key Parameters
7.2. List of Publications Focused on Novel Antibody Therapies
- 7.2.1. Analysis by Year of Publication
- 7.2.2. Word Cloud Analysis: Emerging Focus Areas
- 7.2.3. Analysis by Type of Article
- 7.2.4. Top Authors: Analysis by Number of Publications
- 7.2.5. Key Journals: Analysis by Number of Publications
- 7.2.6. Key Journals: Analysis by Impact Factor
- 7.2.7. Most Popular Publishers: Analysis by Number of Publications
- 7.2.8. Most Popular Copyright Holders: Analysis by Number of Publications

8. PATENT ANALYSIS

8.1. Analysis Methodology and Key Parameters
8.2. List of Patents Focused on Novel Antibody Therapies
- 8.2.1. Analysis by Patent Publication Year
- 8.2.2. Year-wise Trend of Granted Patents
- 8.2.3. Analysis by Type of Patent
- 8.2.4. Analysis by Granted Patents and Patent Applications
- 8.2.5. Analysis by Geography
- 8.2.6. Analysis by CPC Symbols
- 8.2.7. Analysis by Type of Applicant
- 8.2.8. Analysis by Patent Age
- 8.2.9. Word Cloud Analysis: Emerging Focus Areas
- 8.2.10. Leading Industry Players: Analysis by Number of Patents
- 8.2.11. Leading Non-Industry Players: Analysis by Number of Patents
- 8.2.12. Leading Individual Assignees: Analysis by Number of Patents
- 8.2.13. Leading Players: Benchmarking by Patent Characteristics (CPC Symbols)
- 8.2.14. Patent Valuation: Analysis Methodology and Parameters
- 8.2.15. Patent Valuation: Analysis by Relative Valuation

9. PARTNERSHIPS AND COLLABORATIONS

9.1. List of Partnerships and Collaborations Focused on Novel Antibody Therapies
- 9.1.1. Analysis by Year of Partnership
- 9.1.2. Analysis by Type of Partnership
- 9.1.3. Analysis by Year and Type of Partnership
- 9.1.4. Most Popular Drug: Analysis by Number of Partnerships
- 9.1.5. Analysis by Types of Novel Antibodies
- 9.1.6. Analysis by Target Disease Indication(s)
- 9.1.7. Analysis by Type of Partnership and Target Indication(s)
- 9.1.8. Analysis by Type of Partner
- 9.1.9. Most Active Players: Analysis by Number of Partnerships
- 9.1.10. Most Active Players: Analysis by Type of Partnership
- 9.1.11. Regional Analysis of Partnerships
- 9.1.12. Intercontinental and Intracontinental Agreements

10. BIG PHARMA PLAYERS

10.1 Analysis Methodology and Key Parameters
10.2. Scoring Criteria for Key Parameters
10.3. List of Big Pharma Players Focused on Novel Antibody Therapies
- 10.3.1. Analysis by Supplier Strength
- 10.3.2. Analysis by Portfolio Strength
- 10.3.3. Analysis by Portfolio Diversity
- 10.3.4. Benchmarking: Spider Web Analysis
- 10.3.5. Benchmarking: Harvey Ball Analysis
- 10.3.6. Benchmarking: Wind Rose Chart

11. MARKET SIZING AND OPPORTUNITY ANALYSIS

11.1. Forecast Methodology and Key Assumptions
11.2. Global Novel Antibody Therapies Market, 2022-2035
11.3. Product-wise Sales Forecast (Marketed Drugs)
- 11.3.1. Adcetris (Seagen)
  - 11.3.1.2. Sales Forecast
- 11.3.2. Elzonris (Menarini Group)
  - 11.3.2.2. Sales Forecast
- 11.3.3. Pluvicto (Novartis)
  - 11.3.3.2. Sales Forecast
11.4. Global Novel Antibody Therapies Market, 2024 and 2035: Distribution by Type of Novel Antibodies
- 11.4.1 Novel Antibody Therapies Market for Immunocytokines, 2024-2035
- 11.4.2 Novel Antibody Therapies Market for Immunotoxin, 2023-2035
- 11.4.3 Novel Antibody Therapies Market for Radioisotopes Immunoconjugates, 2023-2035
11.5. Global Novel Antibody Therapies Market, 2026 and 2035: Distribution by Target Disease Indication(s)
- 11.5.1 Novel Antibody Therapies Market for Acute Myeloid Leukemia, 2023-2035
- 11.5.2 Novel Antibody Therapies Market for Bladder Cancer, 2023-2035
- 11.5.3 Novel Antibody Therapies Market for Diffuse Large B-cell Lymphoma, 2025-2035
- 11.5.4 Novel Antibody Therapies Market for Graft-versus-host disease, 2026-2035
- 11.5.5 Novel Antibody Therapies Market for Melanoma, 2024-2035
- 11.5.6 Novel Antibody Therapies Market for Prostate Cancer, 2026-2035
- 11.5.7 Novel Antibody Therapies Market for Soft-tissue sarcoma, 2025-2035
11.6. Global Novel Antibody Therapies Market, 2024 and 2035: Distribution by Type of Therapy
- 11.6.1. Novel Antibody Therapies Market for Combination Therapy, 2024-2035
- 11.6.2. Novel Antibody Therapies Market for Monotherapy, 2023-2035
11.7. Global Novel Antibody Therapies Market, 2023 and 2035: Distribution by Route of Administration
- 11.7.1. Novel Antibody Therapies Market for Intratumoral Drugs, 2023-2035
- 11.7.2. Novel Antibody Therapies Market for Intravenous Drugs, 2023-2035
- 11.7.3. Novel Antibody Therapies Market for Intravesical Drugs, 2023-2035
11.8. Global Novel Antibody Therapies Market, 2024 and 2035: Distribution by Geography
- 11.8.1. Novel Antibody Therapies Market in North America, 2023-2035
- 11.8.2. Novel Antibody Therapies Market in Europe, 2025-2035
- 11.8.3. Novel Antibody Therapies Market in Asia Pacific, 2023-2035
11.9. Product-wise Sales Forecast (Phase III Drugs)
- 11.9.1. Adcetris (Seagen)
  - 11.9.1.1. Target Patient Population
  - 11.9.1.2. Sales Forecast
  - 11.9.1.3. Net Present Value
  - 11.9.1.4. Value Creation Analysis
- 11.9.2. Fibromun (Philogen)
  - 11.9.2.1. Target Patient Population
  - 11.9.2.2. Sales Forecast
  - 11.9.2.3. Net Present Value
  - 11.9.2.4. Value Creation Analysis
- 11.9.3. Iomab-B (Actinium Pharmaceuticals)
  - 11.9.3.1. Target Patient Population
  - 11.9.3.2. Sales Forecast
  - 11.9.3.3. Net Present Value
  - 11.9.3.4. Value Creation Analysis
- 11.9.4. Nidlegy (Philogen)
  - 11.9.4.1. Target Patient Population
  - 11.9.4.2. Sales Forecast
  - 11.9.4.3. Net Present Value
  - 11.9.4.4. Value Creation Analysis
- 11.9.5. T-Guard (Xenikos)
  - 11.9.5.1. Target Patient Population
  - 11.9.5.2. Sales Forecast
  - 11.9.5.3. Net Present Value
  - 11.9.5.4. Value Creation Analysis
- 11.9.6. TLX 591 (Telix Pharmaceuticals)
  - 11.9.6.1. Target Patient Population
  - 11.9.6.2. Sales Forecast
  - 11.9.6.3. Net Present Value
  - 11.9.6.4. Value Creation Analysis
- 11.9.7. Vicinium (Sesen Bio)
  - 11.9.7.1. Target Patient Population
  - 11.9.7.2. Sales Forecast
  - 11.9.7.3. Net Present Value
  - 11.9.7.4. Value Creation Analysis

新規抗体療法市場：新規抗体タイプ別、標的適応症別、治療法タイプ別、投与経路別、主要地域別：業界動向と世界の予測、2022年～2035年

Novel Antibody Therapies Market: Distribution by Type of Novel Antibody, Target Indication, Type of Therapy, Route of Administration, and Key Geographical Regions : Industry Trends and Global Forecasts, 2022-2035

目次

第1章序文

第2章エグゼクティブサマリー

第3章イントロダクション

第4章新規抗体療法：市場の市場情勢

第5章企業プロファイル

第6章臨床試験分析

第7章出版物の分析

第8章特許分析

第9章パートナーシップとコラボレーション

第10章製薬大手

第11章市場規模と機会分析

第12章付録1：表形式のデータ

第13章付録2：企業および組織のリスト

LIST OF TABLES

LIST OF FIGURES

INTRODUCTION

SCOPE OF THE REPORT

RESEARCH METHODOLOGY

The secondary sources of information include:

KEY QUESTIONS ANSWERED

CHAPTER OUTLINES

TABLE OF CONTENTS

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION

4. NOVEL ANTIBODY THERAPIES: MARKET LANDSCAPE

5. COMPANY PROFILES

6. CLINICAL TRIAL ANALYSIS

7. PUBLICATION ANALYSIS

8. PATENT ANALYSIS

9. PARTNERSHIPS AND COLLABORATIONS

10. BIG PHARMA PLAYERS

11. MARKET SIZING AND OPPORTUNITY ANALYSIS

12. APPENDIX 1: TABULATED DATA

13. APPNEDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

新規抗体療法市場：新規抗体タイプ別、標的適応症別、治療法タイプ別、投与経路別、主要地域別：業界動向と世界の予測、2022年～2035年

Novel Antibody Therapies Market: Distribution by Type of Novel Antibody, Target Indication, Type of Therapy, Route of Administration, and Key Geographical Regions : Industry Trends and Global Forecasts, 2022-2035

目次

第1章 序文

第2章 エグゼクティブサマリー

第3章 イントロダクション

第4章 新規抗体療法：市場の市場情勢

第5章 企業プロファイル

第6章 臨床試験分析

第7章 出版物の分析

第8章 特許分析

第9章 パートナーシップとコラボレーション

第10章 製薬大手

第11章 市場規模と機会分析

第12章 付録1：表形式のデータ

第13章 付録2：企業および組織のリスト

LIST OF TABLES

LIST OF FIGURES

INTRODUCTION

SCOPE OF THE REPORT

RESEARCH METHODOLOGY

The secondary sources of information include:

KEY QUESTIONS ANSWERED

CHAPTER OUTLINES

TABLE OF CONTENTS

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION

4. NOVEL ANTIBODY THERAPIES: MARKET LANDSCAPE

5. COMPANY PROFILES

6. CLINICAL TRIAL ANALYSIS

7. PUBLICATION ANALYSIS

8. PATENT ANALYSIS

9. PARTNERSHIPS AND COLLABORATIONS

10. BIG PHARMA PLAYERS

11. MARKET SIZING AND OPPORTUNITY ANALYSIS

12. APPENDIX 1: TABULATED DATA

13. APPNEDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

第1章序文

第2章エグゼクティブサマリー

第3章イントロダクション

第4章新規抗体療法：市場の市場情勢

第5章企業プロファイル

第6章臨床試験分析

第7章出版物の分析

第8章特許分析

第9章パートナーシップとコラボレーション

第10章製薬大手

第11章市場規模と機会分析

第12章付録1：表形式のデータ

第13章付録2：企業および組織のリスト